Irene Kuter, D.Phil., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Estradiol | 4 | 2014 | 2020 | 0.460 |
Why?
|
| Breast Neoplasms | 27 | 2022 | 20822 | 0.430 |
Why?
|
| Antineoplastic Agents, Hormonal | 5 | 2014 | 1524 | 0.360 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2012 | 415 | 0.340 |
Why?
|
| Anthracyclines | 4 | 2015 | 288 | 0.330 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 14 | 2021 | 11524 | 0.280 |
Why?
|
| Troponin I | 3 | 2015 | 619 | 0.190 |
Why?
|
| Receptors, Estrogen | 3 | 2014 | 2187 | 0.150 |
Why?
|
| Taxoids | 3 | 2015 | 666 | 0.140 |
Why?
|
| Chemotherapy, Adjuvant | 9 | 2014 | 3479 | 0.140 |
Why?
|
| Doxorubicin | 6 | 2015 | 2234 | 0.140 |
Why?
|
| Cardiotoxins | 1 | 2015 | 41 | 0.130 |
Why?
|
| Cardiac Volume | 1 | 2015 | 210 | 0.120 |
Why?
|
| Echocardiography | 4 | 2015 | 5102 | 0.120 |
Why?
|
| Ventricular Function, Left | 3 | 2015 | 3670 | 0.120 |
Why?
|
| Receptor, erbB-2 | 6 | 2014 | 2416 | 0.120 |
Why?
|
| Keratin-19 | 1 | 2013 | 33 | 0.110 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2013 | 1101 | 0.110 |
Why?
|
| Paclitaxel | 5 | 2005 | 1708 | 0.090 |
Why?
|
| Peroxidase | 1 | 2013 | 611 | 0.090 |
Why?
|
| Ki-67 Antigen | 1 | 2012 | 644 | 0.090 |
Why?
|
| Stroke Volume | 4 | 2015 | 5007 | 0.080 |
Why?
|
| Microbial Collagenase | 1 | 1989 | 122 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 7 | 2021 | 9274 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2014 | 8428 | 0.080 |
Why?
|
| Biological Factors | 1 | 1989 | 164 | 0.080 |
Why?
|
| Carcinoma, Ductal | 1 | 2008 | 101 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2015 | 10943 | 0.080 |
Why?
|
| Receptors, Progesterone | 1 | 2012 | 1097 | 0.070 |
Why?
|
| Estrogens | 1 | 2014 | 1566 | 0.070 |
Why?
|
| Antineoplastic Agents | 5 | 2015 | 13695 | 0.070 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2013 | 934 | 0.070 |
Why?
|
| Deoxycytidine | 2 | 2021 | 826 | 0.070 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2005 | 358 | 0.070 |
Why?
|
| Heart Ventricles | 2 | 2015 | 3821 | 0.070 |
Why?
|
| Neoadjuvant Therapy | 2 | 2014 | 2728 | 0.060 |
Why?
|
| Vinblastine | 2 | 2008 | 502 | 0.060 |
Why?
|
| Tamoxifen | 2 | 2000 | 981 | 0.060 |
Why?
|
| Female | 31 | 2022 | 380194 | 0.060 |
Why?
|
| Carcinoma, Lobular | 1 | 2008 | 484 | 0.060 |
Why?
|
| Heart | 1 | 2015 | 4467 | 0.050 |
Why?
|
| Middle Aged | 19 | 2022 | 213383 | 0.050 |
Why?
|
| Thoracic Vertebrae | 1 | 2006 | 608 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 3703 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2014 | 9438 | 0.050 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2021 | 193 | 0.050 |
Why?
|
| Treatment Outcome | 9 | 2021 | 63114 | 0.050 |
Why?
|
| Natriuretic Peptide, Brain | 3 | 2015 | 1573 | 0.050 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2002 | 349 | 0.050 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2011 | 2073 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2005 | 1770 | 0.040 |
Why?
|
| Spinal Neoplasms | 1 | 2006 | 760 | 0.040 |
Why?
|
| Heart Diseases | 1 | 2012 | 2788 | 0.040 |
Why?
|
| Prognosis | 6 | 2015 | 29063 | 0.040 |
Why?
|
| Humans | 31 | 2022 | 744343 | 0.040 |
Why?
|
| Cardiovascular Diseases | 2 | 2015 | 15165 | 0.040 |
Why?
|
| Estrogen Antagonists | 1 | 1999 | 152 | 0.040 |
Why?
|
| Chemoprevention | 1 | 2001 | 319 | 0.040 |
Why?
|
| Carboplatin | 1 | 2021 | 801 | 0.040 |
Why?
|
| Fibroblasts | 1 | 1989 | 4161 | 0.040 |
Why?
|
| Adult | 19 | 2022 | 214055 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 3508 | 0.040 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2006 | 2016 | 0.040 |
Why?
|
| Antigens, Surface | 1 | 2002 | 1663 | 0.040 |
Why?
|
| Integrins | 1 | 2002 | 846 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2002 | 1537 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2006 | 2645 | 0.030 |
Why?
|
| Fasting | 1 | 2022 | 1593 | 0.030 |
Why?
|
| Mastectomy | 2 | 2014 | 1793 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2014 | 3920 | 0.030 |
Why?
|
| Fatigue | 1 | 2022 | 1531 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2001 | 2924 | 0.030 |
Why?
|
| Time Factors | 5 | 2019 | 40075 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2000 | 11031 | 0.030 |
Why?
|
| Brain Neoplasms | 2 | 2008 | 8863 | 0.030 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2015 | 176 | 0.030 |
Why?
|
| Aged | 9 | 2022 | 163280 | 0.030 |
Why?
|
| Meningeal Neoplasms | 1 | 2003 | 1241 | 0.030 |
Why?
|
| Mammography | 1 | 2005 | 2476 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2002 | 1988 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 2 | 2014 | 6314 | 0.030 |
Why?
|
| Galectin 3 | 1 | 2015 | 227 | 0.030 |
Why?
|
| Cyclophosphamide | 3 | 2005 | 2242 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2014 | 15076 | 0.030 |
Why?
|
| Catheters, Indwelling | 1 | 1995 | 426 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2022 | 8324 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2014 | 549 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2015 | 552 | 0.030 |
Why?
|
| Prospective Studies | 5 | 2022 | 53288 | 0.030 |
Why?
|
| Europe | 1 | 2019 | 3339 | 0.030 |
Why?
|
| Clinical Trials as Topic | 2 | 2014 | 7913 | 0.030 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 4851 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 57776 | 0.030 |
Why?
|
| Troponin C | 1 | 2011 | 25 | 0.020 |
Why?
|
| Peptide Fragments | 2 | 2015 | 5097 | 0.020 |
Why?
|
| Piperidines | 1 | 1999 | 1602 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2006 | 6234 | 0.020 |
Why?
|
| Catheterization, Central Venous | 1 | 1995 | 514 | 0.020 |
Why?
|
| Carcinoma | 1 | 2002 | 2375 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2002 | 4560 | 0.020 |
Why?
|
| Pneumonia | 1 | 2001 | 2133 | 0.020 |
Why?
|
| Rabbits | 2 | 2002 | 4894 | 0.020 |
Why?
|
| Survival Analysis | 3 | 2013 | 10252 | 0.020 |
Why?
|
| Disease-Free Survival | 2 | 2014 | 6895 | 0.020 |
Why?
|
| Follow-Up Studies | 3 | 2015 | 39050 | 0.020 |
Why?
|
| North America | 1 | 2012 | 1249 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 9239 | 0.020 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1989 | 821 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 2005 | 4933 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2013 | 2618 | 0.020 |
Why?
|
| Myocardial Contraction | 1 | 2012 | 1585 | 0.020 |
Why?
|
| Retrospective Studies | 5 | 2022 | 77449 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 4751 | 0.020 |
Why?
|
| Risk Factors | 4 | 2015 | 72290 | 0.020 |
Why?
|
| Breast | 1 | 2015 | 1969 | 0.020 |
Why?
|
| Neoplasms | 1 | 2015 | 21683 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 3508 | 0.020 |
Why?
|
| Disease Progression | 2 | 2019 | 13284 | 0.020 |
Why?
|
| Postmenopause | 1 | 2014 | 2461 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2014 | 4217 | 0.020 |
Why?
|
| Palpation | 1 | 2005 | 167 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 1799 | 0.020 |
Why?
|
| Radiation Pneumonitis | 1 | 2005 | 104 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 3505 | 0.020 |
Why?
|
| Extracellular Fluid | 1 | 2005 | 167 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 3778 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2012 | 2866 | 0.010 |
Why?
|
| Integrin alpha6beta4 | 1 | 2002 | 31 | 0.010 |
Why?
|
| Massachusetts | 1 | 2015 | 8663 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1999 | 9959 | 0.010 |
Why?
|
| Cohort Studies | 3 | 2013 | 40561 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 2002 | 919 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 1999 | 5442 | 0.010 |
Why?
|
| Quality of Life | 1 | 2022 | 12804 | 0.010 |
Why?
|
| Cornea | 1 | 1989 | 1524 | 0.010 |
Why?
|
| Antibodies, Neoplasm | 1 | 2002 | 286 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2001 | 876 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 13989 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2014 | 13033 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2005 | 2879 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 12245 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2005 | 1869 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 6538 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2005 | 35421 | 0.010 |
Why?
|
| Cause of Death | 1 | 2008 | 3584 | 0.010 |
Why?
|
| Logistic Models | 1 | 2012 | 13408 | 0.010 |
Why?
|
| Menopause | 1 | 2005 | 1626 | 0.010 |
Why?
|
| Incidence | 1 | 2015 | 20947 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2005 | 5078 | 0.010 |
Why?
|
| Skin | 1 | 1989 | 4364 | 0.010 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 1999 | 624 | 0.010 |
Why?
|
| Fluorouracil | 1 | 1999 | 1619 | 0.010 |
Why?
|
| Cytokines | 1 | 1989 | 7322 | 0.010 |
Why?
|
| Survival Rate | 1 | 2008 | 12788 | 0.010 |
Why?
|
| Ribs | 1 | 1995 | 252 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1989 | 19229 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2005 | 5985 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2014 | 23403 | 0.010 |
Why?
|
| Radiology, Interventional | 1 | 1995 | 460 | 0.010 |
Why?
|
| United States | 1 | 2019 | 69872 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2012 | 23338 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2003 | 8642 | 0.010 |
Why?
|
| Veins | 1 | 1995 | 770 | 0.010 |
Why?
|
| Cardiomyopathies | 1 | 2001 | 1912 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 1995 | 1415 | 0.000 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 19905 | 0.000 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 14722 | 0.000 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 1999 | 5172 | 0.000 |
Why?
|
| Animals | 2 | 2002 | 168757 | 0.000 |
Why?
|
| Lung | 1 | 2001 | 9856 | 0.000 |
Why?
|
| Inflammation | 1 | 2001 | 10638 | 0.000 |
Why?
|
| Male | 1 | 2015 | 350118 | 0.000 |
Why?
|
| Mice | 1 | 2002 | 81183 | 0.000 |
Why?
|